|Dr. Gerrit Klaerner||Founder, Pres, CEO & Exec. Director||719.98k||N/A||1971|
|Mr. Geoffrey M. Parker||COO, CFO & Exec. VP||502.33k||N/A||1965|
|Dr. Wilhelm Stahl||Exec. VP & CTO||472.06k||18.61k||1960|
|Mr. Robert L. McKague J.D.||Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer||486.46k||N/A||N/A|
|Dr. Dawn Parsell Ph.D.||Exec. VP of Clinical Devel.||504.92k||666.12k||1962|
|Ms. Annie Yoshiyama||VP of Fin. & Chief Accounting Officer||N/A||N/A||1983|
|Jackie Cossmon||VP of Investor Relations & Communications||N/A||N/A||N/A|
|Mr. Edward J. Hejlek Esq., J.D.||Exec. VP of Intellectual Property||N/A||N/A||1957|
|Mr. Marc Cobo||Consultant||N/A||N/A||1980|
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer that has completed phase 3 trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Tricida, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 9. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 9; Compensation: 10.